Idiopathic pulmonary fibrosis: an update on pathogenesis

Q Mei, Z Liu, H Zuo, Z Yang, J Qu - Frontiers in pharmacology, 2022 - frontiersin.org
Idiopathic pulmonary fibrosis (IPF) is a progressive, lethal fibrotic lung disease that occurs
primarily in middle-aged and elderly adults. It is a major cause of morbidity and mortality …

Idiopathic pulmonary fibrosis: an update

P Spagnolo, N Sverzellati, G Rossi, A Cavazza… - Annals of …, 2015 - Taylor & Francis
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal form of idiopathic
interstitial pneumonia. The disease, which occurs primarily in middle-aged and older adults …

Idiopathic pulmonary fibrosis: Disease mechanisms and drug development

P Spagnolo, JA Kropski, MG Jones, JS Lee… - Pharmacology & …, 2021 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life …

Progress in understanding and treating idiopathic pulmonary fibrosis: Recent insights and emerging therapies

H Guo, J Sun, S Zhang, Y Nie, S Zhou… - Frontiers in …, 2023 - frontiersin.org
Idiopathic pulmonary fibrosis (IPF) is a long-lasting, continuously advancing, and irrevocable
interstitial lung disorder with an obscure origin and inadequately comprehended …

Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies

B Selvarajah, M Platé, RC Chambers - Molecular Aspects of Medicine, 2023 - Elsevier
Fibrosis is the concluding pathological outcome and major cause of morbidity and mortality
in a number of common chronic inflammatory, immune-mediated and metabolic diseases …

Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy

P Spagnolo, TM Maher, L Richeldi - Pharmacology & therapeutics, 2015 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …

Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches

DS Glass, D Grossfeld, HA Renna, P Agarwala… - Respiratory …, 2020 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease with high mortality that
commonly occurs in middle-aged and older adults. IPF, characterized by a decline in lung …

Current and future treatment landscape for idiopathic pulmonary fibrosis

F Bonella, P Spagnolo, C Ryerson - Drugs, 2023 - Springer
Idiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis
is complex and encompasses multiple molecular pathways. The first-generation antifibrotics …

Pharmacological treatment of idiopathic pulmonary fibrosis: current approaches, unsolved issues, and future perspectives

M Kreuter, F Bonella, M Wijsenbeek… - BioMed research …, 2015 - Wiley Online Library
Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a 5‐year survival of
approximately 20%. The disease primarily occurs in elderly patients. IPF is a highly …

Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment

TM Maher - Clinics in chest medicine, 2012 - chestmed.theclinics.com
Idiopathic pulmonary fibrosis is a nonmalignant disease, yet it carries a prognosis akin to, or
even worse than, many cancers. Until recently, lung transplantation has been the only …